Ipsen has completed acquisition of a portfolio of five consumer healthcare products from Sanofi.
The company’s new portfolio additions include five products that can be sold in certain European countries. The most significant product is Prontalgine, an analgesic for the treatment of moderate to severe pain, only sold in France.
The portfolio also includes Buscopan, an antispasmodic (sold in the Czech Republic, Estonia, Hungary, Latvia, Poland and Slovakia), Suppositoria Glycerini, a laxative (sold in the Czech Republic), as well as Mucothiol and Mucodyne, expectorants for cough and flu, sold respectively in Greece and the Republic of Ireland, the company said.
This transaction strengthens the evolution of Ipsen Consumer Healthcare portfolio in France and Central Europe with the strategic intent to further develop the OTx1 model in most geographies, Ipsen said in its press release.